Regulation - Abilify, Neurological

Filter

Current filters:

AbilifyNeurological

Popular Filters

Alkermes leaps on positive Ph III results for aripiprazole lauroxil for schizophrenia

Alkermes leaps on positive Ph III results for aripiprazole lauroxil for schizophrenia

09-04-2014

US biotech firm Alkermes saw its shares spike on Tuesday, after it announced positive top-line results…

AbilifyAlkermesaripiprazole lauroxilBiotechnologyLundbeckNeurologicalOtsukaRegulationResearch

UK's NICE plans to recommend Abilify for children with bipolar disorder

10-06-2013

UK drugs watch dog the National Institute for Health and Care Excellence (NICE) has issued new draft…

AbilifyEuropeLundbeckNeurologicalOtsukaPharmaceuticalPricingRegulation

Otsuka files Abilify, first antipsychotic for major depressive disorder in Japan

04-09-2012

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4768) has filed an additional indication for Abilify (aripiprazole)…

AbilifyAsia-PacificNeurologicalOtsukaPharmaceuticalRegulation

USA: FDA panel votes against Regeneron gout drug; Court upholds Abilify patent

09-05-2012

The US Food and Drug Administration's Arthritis Advisory Committee yesterday voted unanimously (11 to…

AbilifyAnti-Arthritics/RheumaticsArcalystBristol-Myers SquibbLegalNeurologicalNorth AmericaOtsukaPatentsPharmaceuticalRegeneronRegulation

COMPANY SPOTLIGHT

Menarini

Back to top